Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Sales | 5,636,700 | 5,092,200 | 5,637,601 | 5,306,900 | 5,585,000 |
| Cost of Goods | 1,124,900 | 1,138,700 | 1,129,900 | 1,152,900 | 1,234,300 |
| Gross Profit | 4,511,800 | 3,953,500 | 4,507,699 | 4,154,000 | 4,350,700 |
| Operating Expenses | 3,014,400 | 3,309,100 | 3,608,400 | 2,811,900 | 4,355,900 |
| Operating Income | 1,498,300 | 645,101 | 900,200 | 1,343,000 | -4,900 |
| Other Income | -32,400 | 85,999 | 31,400 | -1,900 | 46,600 |
| Pre-tax Income | 1,465,900 | 731,100 | 931,600 | 1,341,100 | 41,700 |
| Income Tax | 138,700 | 170,000 | -189,800 | 247,500 | 273,300 |
| Net Income Continuous | 1,327,200 | 561,100 | 1,121,400 | 1,093,600 | -231,600 |
| Net Income Discontinuous | N/A | 3,680,500 | 3,600 | 55,900 | -28,300 |
| Net Income | $1,327,200 | $4,241,600 | $1,125,000 | $1,149,500 | $-259,900 |
| EPS Basic Total Ops | 1.44 | 4.33 | 1.10 | 1.13 | -0.25 |
| EPS Basic Continuous Ops | 1.44 | 0.57 | 1.11 | 1.07 | -0.22 |
| EPS Basic Discontinuous Ops | N/A | 3.76 | -0.01 | 0.06 | -0.03 |
| EPS Diluted Total Ops | 1.44 | 4.31 | 1.10 | 1.12 | -0.25 |
| EPS Diluted Continuous Ops | 1.44 | 0.57 | 1.09 | 1.07 | -0.22 |
| EPS Diluted Discontinuous Ops | N/A | 3.74 | 0.01 | 0.05 | -0.03 |
| EBITDA(a) | $1,745,700 | $1,001,601 | $1,245,701 | $1,758,500 | $420,300 |